GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Phase 1 Study of Levocetirizine
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT02447393
- Locations
- 🇯🇵
GSK Investigational Site, Kagoshima, Japan
Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic Reactivity in Subjects Completing Treatment in Study TL7116958
Phase 2
Completed
- Conditions
- Asthma and Rhinitis
- Interventions
- Other: Pollen allergen extract
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT02446613
- Locations
- 🇨🇦
GSK Investigational Site, Kingston, Ontario, Canada
Combined Study - Phase 3b MenB Long Term Persistence in Adolescents
Phase 3
Completed
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 531
- Registration Number
- NCT02446743
- Locations
- 🇨🇱
GSK Investigational Site, Santiago, Chile
A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 423
- Registration Number
- NCT02446418
- Locations
- 🇩🇪
GSK Investigational Site, Magdeburg, Germany
Clinical Efficacy of Fluoride Toothpastes Using an In Situ Caries Model
Not Applicable
Withdrawn
- Conditions
- Dental Caries
- Interventions
- Drug: Toothpaste containing 1150ppm FOther: Toothpaste containing 0ppm FDrug: Toothpaste containing 250ppm F
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02436473
Study Comparing Blood Levels of Fatty Acids After Consuming Two Forms of Cod Liver Oil
Not Applicable
Completed
- Conditions
- Growth and Development
- Interventions
- Other: Non-emulsified cod liver oil productOther: Emulsified cod liver oil product
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT02428699
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Efficacy of a Carbohydrate Drink on Speed, Agility and Power in School Going Children
Not Applicable
Completed
- Conditions
- Growth and Development
- Interventions
- Other: WaterDietary Supplement: Carbohydrate beverage powderDietary Supplement: Calorie matched beverage powder
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT02428127
- Locations
- 🇮🇳
GSK Investigational Site, Pune, India
A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)
Phase 4
Completed
- Conditions
- Rhinitis, Allergic, Perennial and SeasonalRhinitis, Allergic
- Interventions
- Drug: FFNSOther: Placebo
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 358
- Registration Number
- NCT02424539
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264
Phase 1
Completed
- Conditions
- Urticaria
- Interventions
- Drug: GSK2646264 0.5% topical creamDrug: GSK2646264 1% topical creamDrug: Placebo
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 34
- Registration Number
- NCT02424799
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Effect of Topical Application of Iodex® Balm on Local Surface Temperature
Phase 4
Completed
- Conditions
- Pain
- Interventions
- Drug: IODEX® balmOther: Placebo balm
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT02424565
- Locations
- 🇮🇳
GSK Investigational Site, Indiranagar, Banglador, India
© Copyright 2025. All Rights Reserved by MedPath